InvestorsHub Logo
icon url

falconer66a

08/23/17 11:46 AM

#116767 RE: Cbdpotential #116744

Anavex Will Be Bigger Than Presently Envisioned

Would improving/restoring mitochondrial function/homeostasis synergistically benefit antibiotic use?

Maybe we can use a little 2-73 or 3-71 etc and a little less antibiotics in the future...



For those who, understandably, question my visionary perspectives on Anavex molecules, read no further. My comments will be merely greater confirmations of my stratospheric, mostly nebulous projections for Anavex.

Were I to write an academic paper on the topic, it would be 10 or 20 pages, with dozens of citations and references. Not going to do that; would be a fruitless effort. No one of consequence has any business pondering my contestable imaginations, regardless of any textual elegance.

The summary of my thoughts and findings on the matter are this. I believe the present focus on Alzheimer's, Parkinson's, Rett, and a few other diseases, fails to illuminate the eventual global applications of Anavex technologies, both geographically and medically.

The essence of the matter is this. (I'll try to stay brief.)

The genome, nucleotide (DNA) sequences, codes for the production of, for the most part, elegantly folded proteins, enzymes specifically. These, as in the lock-and-key depiction, absolutely control cellular chemical reactions. The presence of the right enzymes directly cause the right reactions, which is health, or, in consideration of the stimulus and response interaction that the genome directs, it's "homeostasis." In proper cellular homeostasis, when the cell detects that it needs something, effective enzymes are produced to create the new chemicals (or to suppress and eliminate bad ones, such as beta-amyloids and tau tangles in Alzheimer's).

Here's the deal. In so many pathological conditions, health-giving enzymes are mis-folded or absent. This is because enzyme synthesis in the endoplasmic reticula is aberrant, not working. And that's because the ER have become dislodged, disconnected to the energy-supplying mitochondria. Get those two organelles back together, and good, proper, health-giving enzymes can once again be formed.

And that's what the Anavex sigma1-1 receptor agonists do. Inasmuch as mitochondrial mis-function is a sole or contributing cause of so many diseases, far beyond the three or four presently in the Anavex spotlight, just a multitude of diseases have the eventual prospect of successful treatment or prevention by Anavex Life Science Corp.

And yes, there may well be an Anavex/antibiotic synergism, with consequent benefits.

To use a phrase that so interestingly has appeared lately, we are seeing but the emerged tip of the pathology treatment iceberg.

I'd love to get into the Anavex-endorsed or supported labs. I'm betting a bunch of post-docs are busy and excitingly dosing lab rodents with several Anavex molecules, against a host of human-model murine diseases. What they have found would clearly be masked by a non-disclosure agreement (NDA), keeping the results in the Anavex closet for propitious future openings. But, I'm sure, back in those labs it's not just CNS diseases.

I see two giant medical revolutions for the rest of this century. First, the Anavex Revolution, as touched upon above.

The second, much better known, more accepted, and now coming into greater use, will be genomic editing, fixing bad genes with CRISPR technology. That's another story. I won't say anything about it here (off topic altogether).

[I've also pondered agricultural and veterinary applications for Anavex technologies. Utterly gigantic. By mass, more antibiotics in orders of magnitude are sold and used for animals than humans.]

Ok, one other, final thought (really).

Readers of every sort have read the many postings on Anavex here on this Ihub board. Virtually every plausible perspective has been presented, most appropriately. Interesting in their absence, however, have been postings by anyone, of any level of expertise, telling specifically just why the Anavex sigma-1 receptor agonists can't or don't work as the company tells. The Anavex mechanism of action has simply never been effectively or plausibly challenged. The science is real, if not yet fully explored and applied.